In the landscape of infectious disease prevention, the Group ACYW1335 Meningococcal Polysaccharide Vaccine stands as a cornerstone for public health safety. Meningococcal meningitis, caused by Neisseria meningitidis, remains a significant threat worldwide, with the serogroups A, C, Y, and W-135 being responsible for the majority of invasive disease cases. As a leading wholesale supplier, Jiangxi Serum Pharma Industries Co., Ltd. provides not just a product, but a comprehensive service infrastructure designed to support national immunization programs, corporate health initiatives, and emergency outbreak responses.
Our commitment to E-E-A-T (Experience, Expertise, Authoritativeness, and Trustworthiness) ensures that every dose delivered meets the most stringent international quality standards, from GMP-certified manufacturing to validated cold-chain logistics.
The ACYW1335 vaccine utilizes purified capsular polysaccharides. Our current manufacturing ensures low endotoxin levels and high molecular weight integrity, providing robust short-to-medium term immunity suitable for travelers and epidemic control.
Moving forward, we are investing in advanced protein conjugation techniques (utilizing CRM197 or Tetanus Toxoid carriers). This transition aims to induce T-cell dependent immune responses, offering longer-term protection and herd immunity benefits.
Our R&D roadmap includes the optimization of lyophilized (freeze-dried) formulations, enhancing thermal stability for easier distribution in regions with challenging cold-chain infrastructure, such as the African "Meningitis Belt."
We provide full documentation support for WHO pre-qualification and national regulatory approvals, ensuring seamless participation in large-scale public health tenders.
As mandatory requirements for international travelers to high-risk zones, we offer bulk wholesale solutions for specialized travel clinics and religious organizations.
Our rapid-response manufacturing capability allows us to surge production and mobilize inventory during sudden regional outbreaks, saving lives through speed.
Jiangxi Serum Pharma operates at the intersection of biotechnology and digital transformation. Our "Factory 4.0" initiative integrates AI-driven batch monitoring and automated sterile filling lines, significantly reducing human error and increasing yield.
Jiangxi Serum Pharma Industries Co., Ltd. is a professional supplier of pharmaceutical and nutritional products in China. For nearly 10 years, we have been dedicated to exporting biological products, vaccines, Western medicines, raw materials, intermediates, medical consumables, food additives, and plant extracts, and have accumulated rich industry experience.
Established in 2017, we have grown into a powerhouse in the medical export sector, boasting over 500 long-term cooperation clients and 200 close-related suppliers.
Serum Pharma continuously monitors the development of cutting-edge markets. Currently, we have already cooperated with our partners on the customization of:
We provide localized dossier support for ASEAN, African, and Middle Eastern markets, facilitating CTD/eCTD submissions for national drug authority approvals.
Vaccines are sensitive. We utilize world-class thermal packaging and real-time GPS temperature monitoring to ensure the cold chain is never broken from our door to yours.
Recognizing the scale of national health projects, we offer tailored financial and credit solutions for verified institutional buyers and government entities.
